• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Apollo Endosurgery, Inc. - Common Stock (NQ:APEN)

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, Apr 3, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Apollo Endosurgery, Inc. - Common Stock

    < Previous 1 2 Next >
    Apollo Endosurgery Announces Two Important Milestones in the Advancement of Endoscopic Procedures for Patients Living with Obesity
    Via ACCESSWIRE
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Apollo Endosurgery, Inc. (Nasdaq - APEN), Imago BioSciences, Inc. (Nasdaq - IMGO), Opiant Pharmaceuticals Inc. (Nasdaq - OPNT), Benefitfocus, Inc. (Nasdaq - BNFT)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    APOLLO ENDOSURGERY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apollo Endosurgery, Inc. - APEN
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Apollo Endosurgery to be Acquired by Boston Scientific
    Via ACCESSWIRE
    Apollo Endosurgery, Inc. Reports Record $19.6 million Global Revenue in Third Quarter 2022
    Via ACCESSWIRE
    Endoscopic Sleeve Gastroplasty (ESG) Procedure Featured as a "Top 10" Paper at the IFSO 2022 World Congress in Miami
    Via ACCESSWIRE
    Apollo Endosurgery (NASDAQ: APEN) Enters Into Agreement to be Acquired by Boston Scientific (NYSE: BSX) for $615 Million
    Apollo Endosurgery, Inc. (NASDAQ: APEN) is a medical technology company, which is focused on the research and development of advanced, 
    Via Spotlight Growth
    APEN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Apollo Endosurgery, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Apollo Endosurgery Completes Transition to European MDR Requirements for the OverStitch Systems, BIB and Orbera 365 intragastric balloons, and OverTube.
    Via ACCESSWIRE
    Apollo Endosurgery to Participate in Upcoming Investor Conferences
    Via ACCESSWIRE
    Apollo Endosurgery, Inc. Reports Record Global Revenue in Second Quarter 2022
    Via ACCESSWIRE
    Apollo Endosurgery Announces Publication in the Lancet of Landmark Study for the Endoscopic Sleeve Gastroplasty Procedure
    Via ACCESSWIRE
    Apollo Endosurgery to Report Third Quarter Results on November 1, 2022
    Via ACCESSWIRE
    Apollo Endosurgery Announces Publication in the Lancet of Landmark Study for the Endoscopic Sleeve Gastroplasty Procedure
    Publication of MERIT Study Follows FDA Market Authorization of Apollo ESG™ 
    From Apollo Endosurgery, Inc.
    Via AccessWire
    Apollo Endosurgery to Report Second Quarter Results on August 2, 2022
    Via ACCESSWIRE
    Apollo Endosurgery to Report Second Quarter Results on August 2, 2022
    AUSTIN, TX / ACCESSWIRE / July 21, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and... 
    From Apollo Endosurgery, Inc.
    Via AccessWire
    FDA Grants De Novo Marketing Authorization to Apollo Endosurgery for Apollo ESG(TM) and Apollo REVISE(TM), New Endoscopic Systems for Patients with Obesity
    Systems Offer Effective, Minimally Invasive Treatment Options for Millions of Patients with Obesity (BMI 30-50 kg/m2) 
    From Apollo Endosurgery, Inc.
    Via AccessWire
    FDA Grants De Novo Marketing Authorization to Apollo Endosurgery for Apollo ESG and Apollo REVISE, New Endoscopic Systems for Patients with Obesity
    Via ACN Newswire
    Sharon O'Keefe Joins Apollo Endosurgery Board of Directors
    Seasoned healthcare leader brings 30 years of hospital system and medical technology expertise 
    From Apollo Endosurgery, Inc.
    Via AccessWire
    Digestive Disease Week 2022 Adds to the Growing Wave of Clinical Evidence Supporting Significant Opportunity for Apollo Endosurgery Products
    AUSTIN, TX / ACCESSWIRE / May 31, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures,... 
    From Apollo Endosurgery, Inc.
    Via AccessWire
    Apollo Endosurgery Products to Take Center Stage at Digestive Disease Week
    AUSTIN, TX / ACCESSWIRE / May 18, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures,... 
    From Apollo Endosurgery, Inc.
    Via AccessWire
    Apollo Endosurgery, Inc. Reports 33% U.S. Revenue Growth in First Quarter 2022
    Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
    From Apollo Endosurgery, Inc.
    Via AccessWire
    Apollo Endosurgery to Report First Quarter Results on May 3, 2022
    AUSTIN, TX / ACCESSWIRE / April 13, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (Nasdaq:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and... 
    From Apollo Endosurgery, Inc.
    Via AccessWire
    Apollo Endosurgery Appoints Jeannette Bankes to Board of Directors
    Veteran Brings 30 Years of Multinational Healthcare Leadership Experience AUSTIN, TX / ACCESSWIRE / April 4, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally... 
    From Apollo Endosurgery, Inc.
    Via AccessWire
    Apollo Endosurgery to Participate in the Cowen Healthcare Conference
    AUSTIN, TX / ACCESSWIRE / March 2, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today... 
    From Apollo Endosurgery, Inc.
    Via AccessWire
    Apollo Endosurgery, Inc. Reports 50% Revenue Growth in 2021
    - Increased adoption across all product lines in both U.S. and international - Grew fourth quarter 2021 revenue 26% AUSTIN, TX / ACCESSWIRE / February 22, 2022 / Apollo Endosurgery, Inc. ("Apollo")... 
    From Apollo Endosurgery, Inc.
    Via AccessWire
    Apollo Endosurgery to Report Fourth Quarter and Full Year Results on February 22, 2022
    AUSTIN, TX / ACCESSWIRE / February 10, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal... 
    From Apollo Endosurgery, Inc.
    Via AccessWire
    Apollo Endosurgery Appoints Keely Scamperle as Vice President of Reimbursement and Market Access
    Veteran Leader Brings 25 Years of Global Medical Device Experience AUSTIN, TX / ACCESSWIRE / January 18, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive... 
    From Apollo Endosurgery, Inc.
    Via AccessWire
    Apollo Endosurgery Announces Preliminary 2021 Revenue Results; Reflecting 50% Growth Over 2020
    Fourth quarter 2021 revenue grew 25% over 2020 AUSTIN, TX / ACCESSWIRE / January 10, 2022 / Apollo Endosurgery, Inc. ("Apollo" or the "Company") (NASDAQ:APEN), a global leader in less invasive medical... 
    From Apollo Endosurgery, Inc.
    Via AccessWire
    Apollo Endosurgery Announces New $100 Million Senior Secured Term Loan Facility from Innovatus Capital Partners, LLC
    - $35 million funded at close to refinance existing debt, extend maturity and lower interest expense - Additional borrowing capacity provides minimally dilutive growth capital and strategic flexibility... 
    From Apollo Endosurgery, Inc.
    Via AccessWire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.